ArticlebioRxiv : the preprint server for biology2025
Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
Abstract
Importance: Anti-amyloid immunotherapy is used to treat Alzheimer disease (AD) with moderate benefits and potentially serious side effects due to amyloid related imaging abnormality with effusions/edema (ARIA-E). Different anti-amyloid antibodies have different Objectives: To determine whether anti-amyloid antibodies bind different species of human brain Aβ and whether these binding properties to human brain Aβ explains ARIA-E rates. Design: Cross-sectional study of 18 postmortem human brains. Setting: Single tertiary care hospital. Participants: Deceased patients with AD and cerebral amyloid angiopathy (CAA). Main Outcomes and Measures: Equilibrium binding constants (K Results: Lecanemab did not bind with greater affinity to the soluble fraction of Aβ compared to aducanumab. All three antibodies were bound essentially identical quantities of Aβ across the 18 cases and fractions (Pearson's r 0.84 - 0.97). Antibody preference for plaque Conclusions and Relevance: The lecanemab binding target in human brain is unlikely to be distinctly "protofibrillar" compared to other antibodies. Differences in antibody preference for plaque
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.